[144] Kymera Therapeutics, Inc. SEC Filing

Rhea-AI Filing Summary

Kymera Therapeutics (KYMR) Form 144 notice reports a proposed sale of 30,000 common shares. The shares are scheduled to be sold through UBS Financial Services on NASDAQ on 09/16/2025 with an aggregate market value of $1,470,000. The filing states 71,497,597 shares outstanding. The 30,000 shares were acquired on 09/16/2025 by exercise of stock options from the issuer and payment was in cash on the same date. The filer reports no securities sold in the past three months and affirms no undisclosed material adverse information.

Insights

Securities Analyst

TL;DR: Routine insider sale notice for 30,000 shares via option exercise; appears procedural and not an earnings or financing event.

The Form 144 documents a proposed sale of 30,000 common shares through UBS with an aggregate value of $1,470,000, indicating the shares were acquired and paid for on 09/16/2025 by exercising options. The filing notes 71,497,597 shares outstanding and reports no other sales in the prior three months. As a compliance filing under Rule 144, it notifies the market of a planned sale but does not disclose company operational or financial performance details.

Corporate Governance Expert

TL;DR: Disclosure meets Rule 144 reporting requirements; signer affirms absence of undisclosed material information.

The notice identifies the broker (UBS Financial Services) and confirms the seller acquired the shares by exercising stock options from the issuer on the same date as the planned sale and payment in cash. The signature representation reiterates the filer does not possess undisclosed material adverse information. The form contains no indication of 10b5-1 plan reliance or other governance arrangements in the remarks section.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	UBS Financial Services, Inc. 11 Madison Ave 4th Floor New York NY 10010	30000	1470000.00	71497597	09/16/2025	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	09/16/2025	Exercise of stock options	Issuer			30000	09/16/2025	Cash

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks

Date of Notice

Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does the KYMR Form 144 disclose about the proposed sale?

The filing discloses a proposed sale of 30,000 common shares through UBS on 09/16/2025 with an aggregate market value of $1,470,000.

How were the 30,000 shares acquired according to the filing?

The shares were acquired on 09/16/2025 by exercise of stock options from the issuer, and payment was made in cash on that date.

Does the filing report recent sales of Kymera securities by the same person?

The filing states Nothing to Report for securities sold during the past three months by the person for whose account the securities are to be sold.

Which broker and exchange are named in the Form 144?

The broker is UBS Financial Services, Inc., 11 Madison Ave, New York and the exchange listed is NASDAQ.

How many Kymera shares are outstanding per the filing?

The filing reports 71,497,597 shares outstanding.